Literature DB >> 8748826

Tenascin distribution in human brain tumours.

P Castellani1, A Dorcaratto, A Siri, L Zardi, G L Viale.   

Abstract

Using a monoclonal antibody specific for human tenascin (TN), 180 intracranial growths were immunohistochemically studied. In 69 cases of meningioma, neoplastic cells were negative, with some positivity being observed only in the perivascular and the supporting stroma, especially in anaplastic meningiomas. In 57 cases of glioma different degrees of reactivity occurred in both the cellular conglomerates and the stromal components of the tumours. A higher variability in reactivity was observed in anaplastic astrocytomas and glioblastomas. The most constant finding of the study was the staining of the stroma, which was observed in all types of growths, including metastasis, abscess and tuberculoma. The results are consistent with the hypothesis that tenascin is a stromal marker rather than a true marker of malignant tumours. The heterogeneous distribution of TN in anaplastic gliomas may be a factor in the variable response to treatment with radiolabelled anti-TN monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8748826     DOI: 10.1007/bf01411434

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  34 in total

Review 1.  Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer.

Authors:  G Nicolò; S Salvi; G Oliveri; L Borsi; P Castellani; L Zardi
Journal:  Cell Differ Dev       Date:  1990-12-02

2.  Enhanced expression of neural cell adhesion molecules and tenascin (cytotactin) during wound healing.

Authors:  C M Chuong; H M Chen
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

3.  Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies.

Authors:  A Siri; B Carnemolla; M Saginati; A Leprini; G Casari; F Baralle; L Zardi
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

4.  Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis.

Authors:  M Higuchi; T Ohnishi; N Arita; S Hiraga; T Hayakawa
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

5.  Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2.

Authors:  P Riva; A Arista; C Sturiale; G Moscatelli; V Tison; M Mariani; E Seccamani; S Lazzari; L Fagioli; G Franceschi
Journal:  Int J Cancer       Date:  1992-04-22       Impact factor: 7.396

6.  Enhanced expression of the developmentally regulated extracellular matrix molecule tenascin following adult brain injury.

Authors:  E D Laywell; U Dörries; U Bartsch; A Faissner; M Schachner; D A Steindler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

7.  Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.

Authors:  E V Colapinto; P A Humphrey; M R Zalutsky; D R Groothuis; H S Friedman; N de Tribolet; S Carrel; D D Bigner
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

Review 8.  Stimulation of tenascin expression in mesenchyme by epithelial-mesenchymal interactions.

Authors:  P Ekblom; E Aufderheide
Journal:  Int J Dev Biol       Date:  1989-03       Impact factor: 2.203

9.  Fibroblasts that proliferate near denervated synaptic sites in skeletal muscle synthesize the adhesive molecules tenascin(J1), N-CAM, fibronectin, and a heparan sulfate proteoglycan.

Authors:  C L Gatchalian; M Schachner; J R Sanes
Journal:  J Cell Biol       Date:  1989-05       Impact factor: 10.539

10.  Induction of tenascin in healing wounds.

Authors:  E J Mackie; W Halfter; D Liverani
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

View more
  6 in total

1.  Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions.

Authors:  H Bouterfa; A R Darlapp; E Klein; T Pietsch; K Roosen; J C Tonn
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

2.  Distribution of tenascin in human malignant gliomas is not related to cell proliferation.

Authors:  P Castellani; A Siri; L Zardi; A Barbanera; A Dorcaratto; G Viale
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

3.  The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Authors:  Chiara Catania; Michela Maur; Rossana Berardi; Andrea Rocca; Anna Maria Di Giacomo; Gianluca Spitaleri; Cristina Masini; Chiara Pierantoni; Reinerio González-Iglesias; Giulia Zigon; Annaelisa Tasciotti; Leonardo Giovannoni; Valeria Lovato; Giuliano Elia; Hans D Menssen; Dario Neri; Stefano Cascinu; Pier Franco Conte; Filippo de Braud
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

4.  A composite hydrogel platform for the dissection of tumor cell migration at tissue interfaces.

Authors:  Andrew D Rape; Sanjay Kumar
Journal:  Biomaterials       Date:  2014-07-19       Impact factor: 12.479

Review 5.  Anti-angiogenic gene therapy in the treatment of malignant gliomas.

Authors:  NaTosha N Gatson; E Antonio Chiocca; Balveen Kaur
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

6.  Immunohistochemical markers for prognosis of ependymal neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Valery Timirgaz
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.